News Image

DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE

Provided By GlobeNewswire

Last update: Sep 23, 2024

Châtillon, France, le 23 septembre 2024 (22 :30 CEST)

DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE

Read more at globenewswire.com

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (2/21/2025, 8:12:30 PM)

After market: 4.4 +0.01 (+0.11%)

4.395

+0.13 (+3.17%)



Find more stocks in the Stock Screener

Follow ChartMill for more